Synthesis and biological evaluation of novel technetium-99m-labeled HYNIC-d-glucose as a potential tumor imaging agent

A conjugate of 6-hydrazinopyridine-3-carboxylic acid (HYNIC) with the d-Glucosamine Hydrochloride (DG) was synthesized though a multiple-step reaction. HYNIC-DG could be labeled successfully and efficiently with ^99mTc using N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine (tricine) and ethylenediamine-N,N′-diacetic acid (EDDA) or tricine and triphenylphosphine-3,3′,3″-trisulfonic acid trisodium salt (TPPTS) as co-ligands to form two ^99mTc-HYNIC-DG complexes ^99mTc-(t/E)HYNIC-DG and ^99mTc-(t/T)HYNIC-DG in high yields (>95 %). The partition coefficient and electrophoresis results indicated they were very hydrophilic and electronegative. The biodistribution studies of two ^99mTc-HYNIC-DG complexes in Kunming mice bearing S 180 tumor showed that ^99mTc-(t/T)HYNIC-DG has more favorable characteristics than ^99mTc-(t/E)HYNIC-DG. High tumor uptake, low or negligible accumulation in non-target organs, and good retention, suggesting ^99mTc-(t/T)HYNIC-DG would be a novel potential tumor imaging agent.     

Synthesis and biodistribution of the 99m TcN-DMSA complex as a potential bone imaging agent

In this study, the preparation of the 99m TcN complex of DMSA (dimercaptosuccinicacid) was carried out as a freeze-dried formulation, through a simple procedureinvolving the initial of 99m TcO 4 – with succinic dihydrazide in thepresence of stannous chloride as reducing agent, followed by the additionof the ligand DMSA to afford the final product. The radiochemical purity ofthe 99m TcN-DMSA complex was over 90% determined by thin layer chromatography.It was stable over 8 hours at room temperature. Its partition coefficientindicated that it was a good hydrophilic complex. Biodistribution in miceshowed that the 99m TcN-DMSA complex was accumulated in bone with high uptakeand good retention, suggesting it would be potentially useful as a bone imagingagent containing the [ 99m TcN] 2+ core. The biodistribution comparison inmice of the 99m TcN-DMSA complex and the 99m Tc-DMSA complex indicate thatthe presence of the 99m Tc nitrido group significantly alters the biologicalproperties of the 99m Tc complex.     

Synthesis and biodistribution of 99mTcN(PDTC)2as a potential brain imaging agent

The preparation of the bis(N-propyl dithiocarbamato) nitrido technetium-99m complex ^99mTcN(PDTC)₂ (PDTC: N-propyl dithiocarbamato) was carried out as a freeze-dried formulation, through a simple procedure involving the initial of ^99mTcO_4- with succinic dihydrazide in the presence of stannous chloride as reducing agent and propylenediamine tetraacetic acid (PDTA) as complexant, followed by the addition of the ligand sodium salt of N-propyl dithiocarbamate to afford the final product. The radiochemical purity of the complex was over 90%, as measured by thin layer chromatography. No decomposition of the complex at room temperature was observed over a period of 12 hours. Its partition coefficient indicated that it was a good lipophilic complex. Biodistribution in mice showed that the complex accumulated in the brain with high uptake. The brain uptake (ID%/g) was 5.07 and the brain/blood ratio 1.34 at 5-minute post-injection. This suggested a potential usefulness of the complex as a brain perfusion imaging agent. This revised version was published online in July 2006 with corrections to the Cover Date.     

Synthesis and biodistribution of 99mTcN(CHIPDTC)2 as a potential myocardial perfusion imaging agent

The bis(N-cyclohexyl, N-isopropyl dithiocarbamato) nitrido technetium-99m complex [^99mTcN(CHIPDTC)₂] (CHIPDTC: N-cyclohexyl, N-isopropyl dithiocarbamato) has been synthesized through a ligand-exchange reaction. The two-step procedure involved the initial reaction of ^99mTcO₄ ^- with succinic dihydrazide (SDH) in the presence of stannous chloride as reducing agent and propylenediamine tetraacetic acid (PDTA) as complexant, followed by the addition of the sodium salt of N-cyclohexyl, N-isopropyl dithiocarbamate. The radiochemical purity (RCP) of the complex was 96±2% as measured by thin layer chromatography (TLC). No decomposition of the complex at room temperature (r. t.) was observed within a period of 6 hours. Its partition coefficient indicated that it was a lipophilic complex. The electrophoresis results showed that the complex was neutral. Biodistribution in mice indicated that the complex accumulated in the heart with high uptake and good retention. The heart/blood, heart/lung ratio was 6.28 and 1.35, respectively, at 60-minute post-injection, suggesting that it would be a potential myocardial perfusion imaging agent.     

Preparation,characterization and biodistribution of salicylidene- and pyridoxylidene-thyroxine complexes of technetium-99m

New Schiff bases, salicylidene- and pyridoxylidene-thyroxine have been prepared and characterized. They were labeled with^99mTc. The labeling yield of the Schiff bases was over 95%. About 60% of the activity was bound to -globulin and albumin fractions when the labled compounds were incubated with a serum sample. The labeled compounds, after i.v. administration to rats, rapidly cleared from blood and excreted into the small intestine. They appeared to behave as hepatobiliary agents.     

Synthesis and properties of neutral gadolinium and technetium-99m-labeled complexes

Diethylenetriaminepentaacetic di(L-dopa ethyl ester) ligand (DTPA-2LDEE) was synthesized by reaction between diethylenetriaminepentaacetic dianhydride (DTPAA) and L-dopa ethyl ester (LDEE). This ligand reacted with gadolinium chloride and sodium pertechnetate to make the corresponding neutral gadolinium complex Gd-DTPA-2LDEE and technetium-99m-labeled complex ^99mTc-DTPA-2LDEE, respectively. The ligand and complexes were characterized and their properties in vitro and in vivo were also evaluated. Gd-DTPA-2LDEE possessed higher relaxation effectiveness and lower cytotoxicity to human hepatoma HepG-2 cells than Gd-DTPA. ^99mTc-DTPA-2LDEE had enhanced single-photon emission computed tomography (SPECT) signal enhancements of the kidneys in rats and provided longer duration time than that of ^99mTc-DTPA. Therefore, ^99mTc-DTPA-2LDEE can be selectively excreted by the kidneys and used as a potential radioactive probe in SPECT.     

Synthesis and biodistribution of a novel 99mTc nitrido radiopharmaceutical with proline dithiocarbamate as a potential tumor imaging agent

In the present study, proline dithiocarbamate (PRODTC) ligand was radiolabeled with the [^99mTc≡N]²⁺ core successfully to obtain the ^99mTcN-PRODTC complex with high radiochemical purity. No decomposition of the complex at room temperature was observed over a period of 6 h. Its partition coefficient indicated that it was a hydrophilic complex. The electrophoresis results showed that the complex was negative. The biodistribution of ^99mTcN-PRODTC in mice bearing S 180 tumor showed that the complex accumulated in the tumor with a certain uptake. The tumor/blood and tumor/muscle ratios reached 2.19 and 4.54 at 2 h post-injection, suggesting it would be a promising candidate for tumor imaging.     

Synthesis of a technetium-99m-labeled thymidine analog: a potential HSV1-TK substrate for non-invasive reporter gene expression imaging

{2-[5-(2′-Fluoro-2′-deoxyuridin-5-yl)pent-4(E)-enyl] [2-(2-mercaptoethyl)aminoethyl]aminoethanethiolato(3)-N,N′,S,S′}oxo-[^99mTc]technetium(V), a potential viral thymidine kinase substrate, was synthesized by coupling 2′-fluoro-2′-deoxyuridine analog with a N2S2 radiometal chelator, followed by [Tc-99m]technetium conjugation. The chemical structure of the radioactive probe was characterized by ¹H NMR and high resolution MS using Re-188 conjugated mimics. The radiochemical purity and yield were identified as 98% and 42%, respectively.     

Synthesis,characterization and biodistribution of 99mTc-Bioquin-HMPAO (99mTc-BH) as a novel brain imaging agent

Recently, the development of novel brain imaging agents has aroused much interest thanks to limited number of brain cancer or diseases diagnosis agents. It is aimed to synthesize a novel brain imaging agent including a promise for further studies on AD diagnosis potential and investigate its bioaffinity with biodistribution studies on healthy Balb/c mice. A novel radiolabeled agent was synthesized and characterized. Quality control of ^99mTc-BH was performed utilizing solvent extraction and chromatographic (Radio TLC and Radio HPLC) methods. Bioaffinity of the ^99mTc-BH was investigated on male Balb/c mice at various time points (5, 30, 60, 120 min post-injection). Paper electrophoresis showed that ^99mTc-BH has a neutral structure. Radiochemical purity of ^99mTc-BH was over 95 % with appropriate stability for imaging period. Selected brain regions have uptakes over 4 % ID/g following intravenous injection. Hippocampus has uptake approximately 10 % ID/g. ^99mTc-BH has shown brain uptake, so it may prove to be valuable for brain imaging as a novel technetium-labeled agent. Further investigations with AD animal model are our on going effort to show that this agent has AD diagnosis potential.     

Preparation and biodistribution of99mTc-HT18

The preparation of N₁-(octadecylcarbomyl-methy)-ethylenediaminetriacetic acid labelled with^99mTc is described. Reduction of technetium was made using sodium borohydride (procedure A) or stannous chloride (procedure B), and the labelling efficiency was checked by thin layer chromatography. Preliminary studies of biol-behavior of this complex were performed in white rats.     

Synthesis and biodistribution of <Superscript>99m</Superscript>TcN-isopentyl xanthate as a potential myocardial perfusion imaging agent

A novel ^99mTc nitrido xanthate complex ^99mTcN(IPEXT)₂ (IPEXT: isopentyl xanthate) has been synthesized by the reduction of ^99mTcO₄ ⁻ into [^99mTcN]²⁺ with stannous chloride in the presence of succinic dihydrazide and propylenediamine tetraacetic acid, followed by the addition of the corresponding xanthate ligand. The radiochemical purity of the complex was over 90% as measured by thin layer chromatography (TLC). No decomposition of the complex at room temperature was observed over a period of 6 hours. Its partition coefficient indicated that it was a lipophilic complex. The electrophoresis results showed the complex was neutral. Biodistribution in mice showed that the ^99mTcN(IPEXT)₂ complex accumulated in the heart with high uptake. The heart uptake (%IDg) was 8.00% at 5-minute post-injection, but the heart/lung, heart/liver and heart/blood ratios were not high, thereby, restricting the use of the complex as a good myocardial imaging agent.     

Synthesis and biodistribution of a novel <Superscript>99m</Superscript>Tc-DMSA-metronidazole ester as a potential tumor hypoxia imaging agent

The dimercaptosuccinic acid metronidazole ester (DMSAMe) was synthesized and radiolabeled with ^99mTc to form the ^99mTc-DMSAMe complex in high yield. The radiochemical purity of the ^99mTc-DMSAMe complex was over 90%, as measured by TLC and by HPLC, without any notable decomposition at room temperature over a period of 6 h. Its partition coefficient indicated that it was a lipophilic complex. The tumor cell experiment and the biodistribution in mice bearing S 180 tumor showed that the ^99mTc-DMSAMe complex had a certain hypoxic selectivity and accumulated in the tumor with high uptake and good retention. The tumor/blood and tumor/muscle ratios increased with time, suggesting it would be a possible tumor hypoxia imaging agent.     

Formamidine sulfinic acid as reducing agent in technetium-99m rhenium sulfide labelling

Labelling kinetic studies, radiochemical characterization and particle size evaluation of technetium-99m rhenium sulfide colloid using formamidine sulfinic acid as reducing agent are described. Comparison with the same colloid which makes use of Sn-sodium pyrophosphate complex as reducing agent has shown higher labelling yields, simplification of labelling procedure and a longer shelf life when formamidine sulfinic acid is used.     

Preparation of new technetium-99m NNS/X complexes and selection for brain imaging agent

Quantification of regional cerebral blood flow(rCBF) plays an important role in the diagnosis ofvarious cerebrovascular and neurological diseases. Innuclear medicine, brain perfusion imaging can providesituation of whole or regional cerebral blood flowperfusion (CBF or rCBF) to neurologists, help to findabnormality of cerebral blood flow before cere-brovascular and neurological diseases induce patho-logical changes in configuration or structure of brain.They offer important information for …     

Radiolabeling of low molecular weight d-galactose-based glycodendrimer with technetium-99m and biodistribution studies

Glycodendrimers are neoglycoconjugates that can be considered as bioisosters of glycoproteins, since they can mimic the multivalent interactions of lectin-carbohydrate. The ability of glycodendrimers to present multivalent interactions with lectins as compared to a monovalent ligand is referred to as “cluster effect”. It is expected that, because of the cluster effect, glycodendrimers would result in a better association with lectins than mono-carbohydrate anchored systems. Radioisotopes are useful to evaluate biodistribution of molecules. This study is important to obtain information about molecule–receptor interactions. Indeed, such study can provide an exquisite tool to evaluate the affinity of certain molecules to specific areas in the body, leading to the development of new radiopharmaceuticals and/or drug delivery systems. Herein, we describe a d-galactose coated low molecular weight PAMAM G0 dendrimer that was successfully radiolabeled with technetium-99m. Biodistribution studies and scintigraphic images were performed in healthy mice. It was observed high liver uptake which was significantly reduced in blocking studies, indicating hepatic specificity. Therefore, low molecular weight glycodendrimer can be considered as useful platform for selective targeting of drugs to the liver and to assess hepatic function.     

Study on tumor affinity of technetium-99m-labeled radiopharmaceuticals. (1) 99mTc-pertechnetate, 99mTc-human serum albumin, and 99mTc-trasylol]

This paper describes biologic distributions, sequential images and macroautoradiograms of 99mTcO4 (pertechnetate), 99mTc-Sn-HSA (human serum albumin) and 99mTc-Sn-TSL (trasylol) in tumor-bearing mice as the first report on tumor affinity of 99mTc-labeled radiopharmaceutical. (1) Maximum tumor concentration (% administered dose/g of tissue weight) of 99mTcO4, 99mTc-HSA and 99mTc-TSL in Ehrlich's tumor-bearing mice resulted in 2.03+/-0.57 at 1 hr, 4.02+/-0.19 at 3 hr and 1.97+/-0.31 at 1 hr respectively. (2) However, tumor to blood concentration ratio of 99mTc-HSA was lowest among them. (3) The corrected tumor accumulation (% 100g dose/g of tissue wt.=% dose/% body weight) of 99mTc-TSL to Ehrlich's tumor in mouse was not different from that of Yoshida's sarcoma in rat, on the contrary to our expectation that the tumor concentration of 99mTc-TSL in them might be different due to differency of the tissue fibrinolytic activity between the respective tumors. (4) Sequential images of the implanted tumor in mouse was best positively delineated with 99mTc-HSA. (5) Macroautoradiograms of Ehrlich's tumor with 99mTcO4, 99mTc-HSA and 99mTc-TSL demonstrated the following findings: all of them were not only accumulated markedly into the tumor cells which were shown as basophilic tissue with H?matoxylin-Eosin staining but also accumulated around the tumor tissue and on the interstitial tissue which were stained as eosinophilic tissue with the above same staining.     

Preparation of L-asparagine complex of technetium-99m

Attempts have been made to employ magnesium oxide as the preconcentration agent for determination of trace metal sin seawater by neutron activation analysis. Hydrous magnesium oxide can efficienthy adsorb most cationic transition metals and rare earths in a simple water system. The adsorption behavior is believed to depend mainly from the association of the cationic species of the metals with MgO ₂ ^2– adsorbent. In seawater matrix some of the metal ions such as Hg²⁺, Ni²⁺, etc. may become inefficiently adsorbed owing to the formation of highly stable metal-chloro complexes with chloride ion. Usually the adsorption efficiencies of the metals can be recovered to be as high as the case in the simple water system if an acidified seawater (to pH1) is subjected to the adsorption experiment. In practice, a large volume of seawater (5 1) is stirred with a small amount of hydrous MgO (1 g). Thereafter, the trace metals adsorbed MgO is separated and taken to be neutron activated. The abundant sodium ion and ubiquitous bromide ion can be obviated by the adsorption process, thereby beneficial to the -spectrometry of the metals enriched on MgO.     

Synthesis and biodistribution of a novel <Superscript>99m</Superscript>Tc complex of HYNIC-conjugated metronidazole as a potential tumor hypoxia imaging agent

A conjugate of 6-hydrazinopyridine-3-carboxylic acid (HYNIC) with the amino analogue of metronidazole (MN) was synthesized through a multiple-step reaction. HYNIC-MN could be labeled easily and efficiently with ^99mTc using N-(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)glycine (tricine) and ethylenediamine -N,N′-diacetic acid (EDDA) as coligands to form the ^99mTc–HYNIC–MN complex in high yield (>95%). Its partition coefficient indicated that it was a good hydrophilic complex. The tumor cell experiment showed that the ^99mTc–HYNIC–MN complex had a certain hypoxic selectivity. The biodistribution studies of ^99mTc–HYNIC–MN in Kunming mice bearing S180 tumor showed a favorable tissue distribution profile with high tumor uptake, and low or negligible accumulation in non-target organs, suggesting ^99mTc–HYNIC–MN would be a novel potential tumor hypoxia imaging agent.     

Preparation,molecular modeling and biodistribution of 99mTc-phytochlorin complex

Phytochlorin [21H, 23H-Porphine-7-propanoicacid, 3-carboxy-5-(carboxymethyl)13-ethenyl-18-ethyl-7,8-dihydro-2,8,12,17-tetramethyl-,(7S,8S)] was labeled with ^99mTc and the factors affecting the labeling yield of ^99mTc-phytochlorin complex were studied in details. At pH 10, ^99mTc-phytochlorin complex was obtained with a high radiochemical yield of 98.4 ± 0.6 % by adding ^99mTc to 100 mg phytochlorin in the presence of 75 μg SnCl₂·2H₂O after 30 min reaction time. The molecular modeling study showed that the structure of ^99mTc-phytochlorin complex presents nearly linear HO–Tc–OH unit with an angle of 179.27° and a coplanar Tc(N1N2N3N4) unit. Biodistribution of ^99mTc-phytochlorin complex in tumor bearing mice showed high T/NT ratio (T/NT = 3.65 at 90 min post injection). This preclinical study showed that ^99mTc-phytochlorin complex is a potential selective radiotracer for solid tumor imaging and afford it as a new radiopharmaceutical suitable to proceed through the clinical trials for tumor imaging.